Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
June 07, 2024 08:18 ET
|
Silo Pharma, Inc.
Analytical testing has confirmed optimal formulation for upcoming studies SARASOTA, FL, June 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental...
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 06, 2024 16:50 ET
|
Silo Pharma, Inc.
SARASOTA, FL, June 06, 2024 (GLOBE NEWSWIRE) -- SARASOTA, FL, June 6, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical...
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
June 05, 2024 08:00 ET
|
Silo Pharma, Inc.
SARASOTA, FL, June 05, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations...
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
June 04, 2024 08:41 ET
|
Silo Pharma, Inc.
Clinical roadmap unveiled for novel and proprietary intranasal PTSD treatment SARASOTA, FL, June 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...
Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
May 21, 2024 08:45 ET
|
Silo Pharma, Inc.
The study has identified a potentially new drug formulation that could potentially extend the period of remission and prevent relapse in patients with depression. SARASOTA, FL, May 21, 2024 (GLOBE...
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
May 14, 2024 08:45 ET
|
Silo Pharma, Inc.
SARASOTA, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations...
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
April 23, 2024 08:15 ET
|
Silo Pharma, Inc.
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”),...
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
April 10, 2024 08:11 ET
|
Silo Pharma, Inc.
SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
March 20, 2024 08:30 ET
|
Silo Pharma, Inc.
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) -- Silo Pharma,...
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
March 18, 2024 07:15 ET
|
Silo Pharma, Inc.
Silo reports positive stability of SP-26 for time-release and dosage control SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a...